TIL Therapy Development Services for Cancer
TIL therapies are innovative strategies to fight solid tumors by harnessing the body's immune system, which have shown promising therapeutic efficacy but still has some limitations. Alfa Cytology specializes in oncology TIL therapeutic development services and our cutting-edge research focuses on preclinical development to pave the way for innovative therapies against cancer.
The Study of TIL Therapy
TIL therapy, or Tumor-Infiltrating Lymphocyte therapy, is a type of cutting-edge cellular immunotherapy. TIL therapy harnesses the power of the immune system to target and eliminate cancer cells. This innovative therapy involves isolating, expanding, and re-injecting TILs back into the body, to unleash a potent anti-tumor immune response, which has been used in the therapeutic of a wide range of malignant tumors such as cervical cancer, squamous cell carcinoma of the head and neck, sarcoma, melanoma, lung cancer, and genitourinary cancer. Research results have shown that compared to many conventional cancer therapeutics such as chemotherapy, IL-2, TIL therapy usually has relatively few side effects. In recent years, several research projects are underway in the field to overcome barriers in the tumor environment to treat more solid tumors and improve the effectiveness of TIL therapies.
Fig.1 How does TIL therapy for cancer work? (Zhao, Y., et al., 2022)
Our Services
Alfa Cytology is dedicated to developing effective TIL-based immunotherapies for a wide range of cancer indications. Whether you are a pharmaceutical company, an academic institution, or a biotech startup, you will receive comprehensive support from our comprehensive TIL therapy solutions. Our service offerings include but are not limited to, the following.
TIL Isolation and Expansion. Utilizing state-of-the-art techniques, we isolate TILs from tumor tissue and expand them ex vivo to obtain a therapeutically relevant number.
Immunophenotyping. Employing flow cytometry and immunohistochemistry, we characterize TIL populations to identify subsets with potent antitumor activity.
TIL Functionality Assays. We conduct functional assays to assess the cytotoxicity and cytokine secretion profile of expanded TILs, ensuring their efficacy in targeting cancer cells.
Genetic Engineering. Implementing gene editing technologies such as CRISPR-Cas9, we modify TILs to enhance their persistence and tumor-targeting capabilities.
Combination Therapies. We explore synergistic effects by combining TIL therapy with other modalities like checkpoint inhibitors or adoptive cell transfer, aiming for improved therapy outcomes.
Our Advantages
Utilizing cutting-edge technology and a multidisciplinary approach, Alfa Cytology is at the forefront of TIL therapeutic innovation. We aim to elucidate the complex interactions of tumor-infiltrating lymphocytes in the tumor microenvironment and unleash their full therapeutic potential for a variety of malignancies.
- Expertise in TIL Biology. A profound understanding of tumor immunology and TIL biology underpins our approach, ensuring precision and efficacy in therapy development.
- High-Throughput Screening. Leveraging automated platforms, we conduct large-scale screenings to identify TIL subsets with optimal antitumor activity, expediting therapy development.
- Next-Generation Sequencing. By employing NGS technologies, we analyze the genomic landscape of tumors and TILs, enabling personalized therapy strategies and biomarker discovery.
- 3D Organoid Models. Utilizing organoid cultures derived from tumors, we mimic the tumor microenvironment to evaluate TIL functionality and optimize therapy protocols.
- Artificial Intelligence. Incorporating machine learning algorithms, we analyze complex datasets to identify predictive biomarkers and optimize TIL therapy efficacy.
Alfa Cytology is committed to driving innovation in cancer therapy through advanced R&D services. We have a comprehensive suite of services including TIL isolation, immunomodulation, biomarker discovery, and research collaborations to support our clients in developing and optimizing a wide range of cancer therapies. Contact us today to learn more about how we can support you in realizing breakthrough cancer therapies.
Reference
- Zhao, Y., et al.; (2022). Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers, 14(17), 4160.
For research use only.
Related Services